Welcome to our dedicated page for West Pharm Svcs SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The West Pharmaceutical Services, Inc. (NYSE: WST) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. West is a Pennsylvania corporation in the surgical and medical instrument manufacturing industry, focused on injectable drug administration for pharmaceutical, biotechnology and generic drug customers.
West’s SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Recent 8-K filings have covered topics such as second- and third-quarter 2025 financial results, updated revenue and adjusted-diluted EPS guidance, and changes in senior leadership, including the appointment of a new Senior Vice President & Chief Financial Officer and the planned departure of a senior legal executive. Other 8-Ks reference the furnishing of earnings press releases and investor presentation materials.
For investors analyzing WST, the 10-K and 10-Q filings contain detailed information on the Proprietary Products and Contract-Manufactured Products segments, High-Value Product Components and Delivery Devices, capital spending, cash flow, and risk factors. Form 8-K filings provide timely updates on material events, including financial results, dividends, guidance changes and executive compensation arrangements.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly identify segment performance, guidance revisions and notable risk disclosures. Real-time updates from the SEC’s EDGAR system ensure that new West filings appear promptly. Users can also review filings that relate to executive appointments, compensation terms and other governance matters, which are often detailed in exhibits to Form 8-K. This page serves as a focused resource for reviewing West Pharmaceutical Services’ regulatory history and ongoing reporting.
West Pharmaceutical Services Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 5,397,791 shares of Common Stock, representing 7.48% of the class. The filing lists sole voting power for 714,505 shares and sole dispositive power for 5,397,791 shares. The filing is signed by Ashley Grim as Head of Global Fund Administration.
West Pharmaceutical Services Inc ownership disclosure: Vanguard Portfolio Management reports beneficial ownership of 4,102,674 shares of Common Stock, representing 5.69% of the class as of 03/31/2026. Vanguard Portfolio Management indicates sole dispositive power over 4,102,674 shares and sole voting power over 8,665 shares. The filing describes holdings managed across Vanguard affiliates and notes the ownership reflects securities held by Vanguard funds and client accounts.
West Pharmaceutical Services senior vice president and chief HR officer Annette F. Favorite exercised stock options and sold shares of common stock. On April 27, she exercised options to acquire 2,817 shares at $83.47 per share and then sold 2,817 shares in an open-market transaction at a weighted average price of $305.2018 per share.
After these transactions, she directly holds 16,828.4906 shares of common stock and indirectly holds 4,966.6170 shares through a Non-Qualified Deferred Compensation Plan, showing she retains a meaningful equity stake in the company despite the net sale.
West Pharmaceutical Services VP and Chief Accounting Officer Chad Winters exercised stock options for 896 shares of common stock at $173.22 per share and on the same day sold 896 shares in an open-market sale at a weighted average price of $300.6688. After these transactions, he directly holds 1,522.81 shares.
West Pharmaceutical Services reported a strong first quarter of 2026 and raised its full-year outlook. Net sales reached $844.9 million, up 21.0% from a year earlier, with organic growth of 15.3%. Diluted EPS rose to $1.92, a 56.1% increase, and adjusted-diluted EPS climbed 46.9% to $2.13 as margins improved.
Growth was driven by the Proprietary Products segment, particularly High-Value Product components and delivery devices, and by demand tied to GLP‑1 obesity and diabetes treatments. Management now guides 2026 net sales to $3.295–$3.350 billion and adjusted-diluted EPS to $8.40–$8.75, both above previous ranges. During the quarter, the company generated free cash flow of $47.2 million and repurchased 1.2 million shares for $297.6 million.
HAUGEN JANET BRUTSCHEA reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Janet Brutschea Haugen received a grant of 52 Phantom Stock Units tied to common stock. The units were valued at $250.64 per unit, bringing her total Phantom Stock Units to about 260.494 held directly.
Footnote disclosures state that Phantom Stock Units will be settled in shares of stock when she terminates service as a director. A separate line shows she directly holds 1,321.258 shares of common stock. Another footnote notes 1,071 restricted stock units and dividend equivalents that vest in full on the date of the next annual shareholder meeting.
The Vanguard Group filed an Amendment to its Schedule 13G/A reporting 0 shares beneficially owned of West Pharmaceutical Services Inc common stock, representing 0% of the class. The filing notes an internal realignment on January 12, 2026 after which certain Vanguard subsidiaries report holdings separately.
West Pharmaceutical Services uses its 2026 proxy to highlight solid 2025 performance and key governance items ahead of the May 4, 2026 virtual annual meeting. Net sales reached $3.1B, up 6.3%, with organic growth of 4.3%. Reported-diluted EPS was $6.79 and adjusted-diluted EPS was $7.29, up 8%, while operating cash flow was $755M and free cash flow $469M, up 70%.
The Board proposes re-electing eleven directors, an annual advisory Say‑on‑Pay vote, ratification of the auditor, and opposes a shareholder proposal for an independent Board chair. The company emphasizes majority‑independent Board oversight, strong risk and cybersecurity frameworks, long‑running dividend growth, and a pay program heavily tied to performance, which received over 94% support in the 2025 Say‑on‑Pay vote. The proxy also notes CEO Eric Green’s intention to retire once a successor is hired in the second half of 2026.
West Pharmaceutical Services, Inc. announced that Eric M. Green, its President, Chief Executive Officer and Chair of the Board, plans to retire from all three roles once a successor is hired to support a smooth leadership transition.
The Board has engaged a leading executive recruiting firm and expects the transition to occur in the second half of 2026. At the same time, the Company reaffirmed its previously issued 2026 financial guidance from its February 12, 2026 earnings release.
Green has led West as President and CEO since April 2015 and became Chair in May 2022. During his tenure, the Company more than doubled sales, achieved total shareholder return of approximately 350%, and generated $3.07 billion in net sales in fiscal 2025.